Achievement of tolerance induction to prevent acute graft-vs.-host disease

Govindarajan Thangavelu, Bruce R. Blazar

Research output: Contribution to journalReview article

4 Scopus citations


Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders. Despite rapid progress in understanding GVHD pathogenesis, broad immunosuppressive agents are most often used to prevent and remain the first line of therapy to treat GVHD. Strategies enhancing immune tolerance in allo-HSCT would permit reductions in immunosuppressant use and their associated undesirable side effects. In this review, we discuss the mechanisms responsible for GVHD and advancement in strategies to achieve immune balance and tolerance thereby avoiding GVHD and its complications.

Original languageEnglish (US)
Article number309
JournalFrontiers in immunology
Issue numberMAR
StatePublished - Jan 1 2019


  • Allogeneic hematopoietic stem cell transplantation
  • Alpha-1 antitrypsin
  • Graft-vs.-host disease
  • Immune tolerance
  • T regulatory cells

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint Dive into the research topics of 'Achievement of tolerance induction to prevent acute graft-vs.-host disease'. Together they form a unique fingerprint.

  • Cite this